Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia
Not Applicable
Recruiting
- Conditions
- Critical Lower Limb IschemiaCritical Limb-Threatening IschemiaCritical Limb Ischemia
- Interventions
- Device: MAGNITUDE BRS
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- R3 Vascular Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06075940
- Locations
- 🇦🇺
Prince of Wales Hopsital, Randwick, New South Wales, Australia
Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
Not Applicable
Not yet recruiting
- Conditions
- Chronic Limb-Threatening Ischemia
- Interventions
- Device: MAGNITUDE Sirolimus-eluting Bioresorbable ScaffoldDevice: Percutaneous Transluminal Angioplasty (PTA)
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- R3 Vascular Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06071429
- Locations
- 🇺🇸
CUMC/NYP, New York, New York, United States
Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease
Not Applicable
Recruiting
- Conditions
- Lower Extremity ClaudicationLower Extremity IschemiaPeripheral Arterial DiseaseAtherosclerotic Lesion
- Interventions
- Device: Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- R3 Vascular Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04912323
- Locations
- 🇮🇹
Maria Cecilia Hospital, Cotignola, Italy
🇨🇦CRCHUM Université Montreal, Montréal, Canada
🇦🇹Medical University Graz, Graz, Austria
© Copyright 2025. All Rights Reserved by MedPath